Methods: Fifty-five women with prospectively confirmed PMD completed a three-arm, RCT in which they were randomized to 3 months of placebo (n = 22), intermittent drospirenone/ethinyl estradiol dosed on a 21-7 schedule (n = 17), or continuous drospirenone/estradiol (n = 16) following a baseline assessment month.
the need for hormonal addback (which causes a recurrence of symptoms; Schmidt et al., 1998) , monophasic combined oral contraceptives (COCs) have been investigated as an alternative method of stabilizing hormones to reduce premenstrual symptoms. Accordingly, several randomized controlled trials (RCTs) have examined COCs containing ethinyl estradiol (EE) and a progestin (e.g., drospirenone or DROS; levonorgestrel or LNG) for the treatment of premenstrual symptoms. Typical 21/7 dosing regimens (21 days active hormone and a 7-day hormone-free interval or HFI) have not demonstrated efficacy compared with placebo (Freeman et al., 2001; Graham & Sherwin, 1992) , whereas two shortened-HFI COC trials (24/4) of DROS/EE have shown some benefit relative to placebo Pearlstein, Bachmann, Zacur, & Yonkers, 2005; Yonkers et al., 2005) , although a review concluded that the efficacy of DROS/EE for PMD may have been overestimated in these previous reports (Lopez, Kaptein, & Helmerhorst, 2012) . Another study examining continuous LNG/EE showed greater effectiveness in the first month of treatment relative to placebo (of note, the first month of COC treatment is associated with greater ovarian suppression; Sullivan, Furniss, Spona, & Elstein, 1999) , but most COC-related improvements were not sustained across follow-up, whereas placebo responses were sustained . Therefore, although studies with shortened or eliminated HFIs have resulted in the most beneficial effects thus far (Marr, Heinemann, Kunz, & Rapkin, 2011; Marr, Niknian, Shulman, & Lynen, 2011; Pearlstein et al., 2005; Yonkers et al., 2005) , additional work is needed to confirm these findings and to clarify the roles of COC regimens (i.e., the use of a shortened or eliminated HFI) versus COC formulations (i.e., the inclusion of different progestins) in the effects of COC on PMD.
Historically, study designs have conflated the roles of COC formulation and regimen. The greater benefit found in DROS/EE 24/4 trials has been attributed to COC formulation with DROS, a progestin with antiandrogen properties; however, the use of the 24/4 regimen, which is associated with greater suppression of ovarian function and steroid fluctuations (Sullivan et al., 1999) , may be responsible. Although COC regimens with longer HFIs (e.g., 21/7) are effective for contraception, 21/7 dosing schedules-and, to a much lesser extent, 24/4 dosing schedules-still permit follicular development during the HFl, which results in continued fluctuations of E2 both during active pills and the HFI (Schlaff, Lynch, Hughes, Cedars, & Smith, 2004; Sullivan et al., 1999) . Therefore, it is possible that the modestly greater efficacy of DROS-containing COCs, which has generally been attributed to the greater antiandrogen properties of DROS, may be more appropriately attributed to the shorter HFIs in those trials.
The purpose of this study was to delineate the role of regimen, holding formulation constant, in the effects of COCs in PMD. If COCs reduce the symptoms of PMD by minimizing susceptible women's exposure to steroid changes, and if such stabilization of hormones is inversely proportional to the length of the HFI (Sulak, Cressman, Waldrop, Holleman, & Kuehl, 1997; Sullivan et al., 1999) , then a reduced or eliminated HFI regimen of any COC (e.g., DROS/EE) should be more effective than a regimen of the same COC dosed on a regimen with a longer HFI. Further, a long-HFI regimen (e.g., 21-7) may result in greater symptom expression during either the HFI Yonkers et al., 2005 ) (due to the rapid increases in endogenous E2 that begin during the HFI (Sullivan et al., 1999) ) or during active pill administration (due to the rapid decreases in endogenous E2 that occur following ovarian suppression (Sullivan et al., 1999) ). In contrast, continuous regimens stabilize ovarian steroids more completely. To date, no study has compared continuous COC to placebo or to intermittent COC; these comparisons are the central goals of the present threearm RCT. To minimize confounds, we utilized the same COC that has been described as efficacious in PMD when administered in a reduced-HFI regimen. We hypothesized that continuous DROS/EE would be associated with greater reductions in mood symptoms compared with placebo and intermittent DROS/EE, whereas intermittent DROS/EE, which allows continued cycling of steroids, would not demonstrate a benefit compared with placebo.
METHODS
The study, carried out between 2010 and 2015 at a single universitybased medical research center in North Carolina, employed a doubleblind, randomized, placebo-controlled trial with three conditions: (1) placebo, (2) intermittently dosed DROS/EE 3 mg/20 g (21/7), and Eligibility criteria were as follows: age 18-40, prospectively confirmed PMD, no medication use except stable thyroid supplementation, no hormonal preparations for 3 months, no current psychiatric treatment with medication or psychotherapy, regular menstrual cycles (21-35 days), no uncontrolled hypertension or end-organ vascular disease, diabetes, or migraine, an unsuspicious PAP smear in the past year, no current pregnancy or breastfeeding, no family history of premenopausal breast cancer or breast cancer in more than one firstdegree relative, no medications or conditions that increase potassium, no history of endometriosis, recent, rapid growth uterine fibroid tumors, hepatic disease, breast carcinoma, pulmonary embolism or phlebothrombosis, undiagnosed vaginal bleeding, porphyria, malignant melanoma, cholecystitis or pancreatitis, or hypercholesterolemia, no diagnosis of an ill-defined, obscure pelvic lesion, no obesity (BMI > 30) in women over 35. Although women with a history of MDD and other mood disorders were included as long as they were in remission for ≥1 year, women with a history of any other psychiatric disorder were excluded unless they had been in remission for ≥2 years.
A prospective diagnosis of PMD was established across two to five screening cycles using the Daily Record of Severity of Problems (DRSP; Endicott & Halbreich, 1982) . These screening cycles were utilized for diagnostic purposes only. Women mailed in responses weekly to discourage retrospective reporting. The DRSP measures each of the 11 premenstrual dysphoric disorder (PMDD) symptom domains listed in the DSM-5, rated on the following scale: 1 = Not at All, 2 = Minimal, 3 = Mild, 4 = Moderate, 5 = Severe, and 6 = Extreme. Women were considered to demonstrate PMD if, for at least one core emotional symptom (DRSP items 1-8), symptoms reached at least a 4 for at least 2 days of the premenstrual week, and the mean symptom severity across at least two premenstrual phases (defined as days -7 to -1 where menses start day is 0) was at least 30% greater than their mean symptom severity across at least two postmenstrual phases (defined as days 4-10 where menses start day is 0). This percent premenstrual elevation above one's postmenstrual baseline was calculated as follows:
(premenstrual mean -postmenstrual mean)/premenstrual mean. Premenstrual impairment was not required for diagnosis given the evidence that many women experience severe premenstrual distress but do not experience significant changes in impairment (Halbreich, 2004; .
We chose to study PMD rather than PMDD for the following reasons: unlike the method of diagnosis described above, the DSM-IV diagnosis of PMDD fails to operationalize the specific numeric criteria for diagnosis using daily ratings, thus rendering the diagnosis ambiguous and ungeneralizable in practice; there are no data demonstrating that women who meet operational criteria for a single core emotional symptom (i.e., demonstration of confinement of a cyclical symptom to the luteal phase) differ from women with multiple symptoms (PMDD) in course, treatment response characteristics, or biology. Nonetheless, we considered women as having DSM-5 PMDD if they met our operationalized PMD criteria on at least one core emotional item and five items total. After screening, participants meeting PMD criteria underwent a SCID-I interview to rule out exclusionary diagnoses. Therefore, all participants met criteria for PMD; 36% (n = 20) of the sample demonstrated symptoms consistent with PMDD.
Participants were randomly assigned to treatment groups by the study's biostatistician in a 1:1:1 ratio using SAS to generate random values corresponding to group assignment. The university's investigational drug service dispensed the medications to study coordinators in a double-blind manner, maintaining the blind for both participants and investigators. Participants were enrolled and monitored by study coordinators. Medication was taken on the prescribed schedule regardless of menstrual or intermenstrual/breakthrough bleeding. Therefore, cycle day in the intermittent and continuous COC groups was considered to be standardized to 28 days during treatment. The premenstrual week was defined at posttreatment in the two active treatment groups as pill days 21-28. In the placebo condition and in baseline and screening months for all participants, the premenstrual week was defined as days -7 to -1, where day 0 is menstrual onset.
The Daily Record of Severity of Problems (DRSP) was also utilized as the primary outcome measure. Several parameters of the DRSP were considered as outcomes in the present study, including mean levels of one's worst baseline symptom, one's worst baseline emotional symptom, physical symptoms (average of items measuring breast tenderness; breast swelling, bloating, or weight gain; and joint or muscle pain), depression (item: "felt depressed, blue"), anxiety (item: "felt anxious," "keyed up," or "on edge"), mood swings (item: "had mood swings (e.g., suddenly felt sad or tearful)"), anger/irritability (average of items "felt angry, irritable" and "had conflicts or problems with people"), and functional impairment (average of three interference items). Although the total DRSP score was originally considered as an outcome, previous analyses of data from the baseline month of this trial demonstrated poor reliability of change over time for the total DRSP score (i.e., items did not change together over time).
Data preparation and analytic plan
Baseline data included two diagnostic screening cycles and one base- Hypotheses were tested by comparing change from baseline cycles to final on-treatment cycle. We analyzed the data only from those compliant subjects who provided at least one complete treatment menstrual cycle. For each outcome, an analysis of covariance model assuming Gaussian errors and with treatment group and baseline value as predictors was fit. Hypothesis tests are reported for whether change from baseline to postbaseline within each treatment group was different from zero and for whether treatment groups differed with respect to this change.
RESULTS
See Figure 1 for CONSORT diagram. Initially, a sample size of 90 participants was selected with the goal of achieving 80% power to detecting conventionally medium (f =.30) differences between treatment groups F I G U R E 1 CONSORT diagram (with alpha set at .05). Due to the stringency of our prospective screening criteria for PMD and time constraints, 75 women were randomized to a treatment arm (Placebo = 25; Intermittent = 25; Continuous = 25). Ten of those randomized did not receive study medication, and an additional 10 discontinued the study prior to the assessment of first-month premenstrual symptoms (see Fig. 1 for details) . Therefore, 55 women provided at least one on-treatment premenstrual week and were included in analyses (Final Sample: Placebo = 22; Intermittent = 17; Continuous = 16). A post hoc power analysis in this final sample indicates that, given alpha set at .05, a sample of 55 women achieves 80% power to detect a conventionally large effect of group on change in premenstrual symptoms over time (smallest detectible effect size, f = .38). Therefore, the present study is powered only to detect conventionally large effects of condition and not conventionally small-tomedium effects.
Demographic characteristics of this sample can be found in Table 1 . Preliminary examination of the worst emotional symptom variable at pretreament revealed that anger/interpersonal conflict was the most common worst symptom (38.4% of women), followed by anxiety (29.09%), mood lability or rejection sensitivity (20%), and finally, depression (12.73%). Worst overall symptoms produced different results; fatigue emerged as the most common worst symptom (21.82%), followed by anger and interpersonal conflict (18.18%), physical symptoms; (12.73%), eating symptoms (10.91%), anxiety (9.09%), depression (7.27%), sleep disturbance (7.27%), mood lability and rejection sensitivity (5.46%), loss of interest (3.64%), overwhelm (1.82%), and feeling out of control (1.82%). These are similar to the worst symptoms reported in previous trials, in which irritability, anxiety, mood lability, and fatigue were the most common worst symptoms (Bloch, Schmidt, & Rubinow, 1997) . Mean total DRSP score during the premenstrual week (days -7 to -1 prior to menses onset) was 70.02 (SD = 19.32). In the largest RCT of DROS conducted , the mean premenstrual symptom score for the DRSP Sum was reported as 77.40 (SD = 16.70); therefore, our sample demonstrated a comparable baseline severity to the sample described by Yonkers et al. (2005) as having PMDD.
Results are presented in Table 2 and mean total DRSP across the baseline and treatment cycles by group are presented in Figure TA B L E 1 Demographic characteristics of study groups 
DISCUSSION
Results of this double-blind, three-arm, randomized, placebocontrolled trial indicated no significant differences in the effects on symptoms of continuous DROS/EE and intermittent (21/7) DROS/EE (neither of which differed from placebo). Just one significant group effect emerged. Intermittent DROS/EE was associated with a less robust reduction in the variance of one's worst baseline symptom when compared to placebo or the continuous DROS/EE.
The symptom reductions observed in the placebo group despite standardized prospective diagnostic screening and the extended nature of the trial (3 months) were remarkable. The strength of this placebo effect is consistent with previous work demonstrating high placebo response rates in psychiatric disorders generally (Fava, Evins, Dorer, & Schoenfeld, 2003) and premenstrual symptoms specifically (Freeman & Rickels, 1999; Halbreich, 2014; Halbreich et al., 2012) .
Many factors known to be associated with high placebo response rates may be relevant to the outcome of the present trial (Fava et al., 2003; Price, Finniss, & Benedetti, 2008) , including the following: the high face validity of a hormonal treatment for premenstrual symptoms, which may enhance expectation of benefit; intensive contact with a single, supportive study coordinator; and use of two active conditions (as the likelihood that any one individual is randomized to an active treatment is positively associated with the size of the placebo effect; Lidstone, Schulzer, & Dinelle, 2010; Rutherford, Sneed, & Roose, 2009; Schatzberg & Kraemer, 2000; Sinyor, Levitt, Cheung, & Schaffer, 2010) .
On the other hand, the present trial had notable strengths with regard to factors known to reduce placebo response, including the use of standardized prospective diagnostic practices, use of outcome measures that are sensitive to change, and a single-site design. Additional work is needed to clarify factors that drive placebo response in PMD, especially the roles of expectation of benefit, validation and social support (Price et al., 2008) , and somatic symptom focus (Geers, Helfer, Weiland, & Kosbab, 2005) .
Although the sample in the present study was not recruited explicitly to meet prospective DSM-IV or DSM-5 criteria for PMDD, which requires at least five symptoms to demonstrate luteal phase elevation and confinement (see Eisenlohr-Moul et al., 2017) , we did recruit women with prospectively documented luteal phase confinement of at least one emotional symptom. Furthermore, mean baseline premenstrual symptom levels in the present study (quantified by DRSP sum score in the baseline premenstrual week) were comparable (70 vs. 77) to that reported in the largest RCT of DROS for PMDD . Therefore, despite the fact that this sample was not recruited for PMDD, it is likely that the results presented herein are generalizable to most women with PMDD. activates the prefrontal cortex and ACC, effects that are critical for efficacy (Petrovic et al., 2005) ; (2) placebo increases theta coupling, suggestive of recruitment of frontally based cognitive control systems (Meyer et al., 2015) ; (3) placebo efficacy in Parkinson's disease leads to release of dopamine in the striatum, the hub of the reward system and a critical player in affective state regulation and valence (De la Fuente-Fernández, 2001; 2002) ; (4) placebo produces attenuated reactivity to negative salient cues and a neural signature associated with cognitive control (Meyer et al., 2015; Petrovic et al., 2005) ; and (5) uncertainty-the expectation of clinical benefit-increases the placebo response (Benedetti, 2012; de la Fuente-Fernández & Stoessl, 2004) . Just as stabilization of hormone levels may provide insights into the triggering of PMD, so the success of placebo in some may suggest the engagement of top-down (prefrontal) cognitive control systems as potentially relevant substrates of affective regulation in PMD.
TA B L E 2 Outcomes within and between treatment groups
We failed to replicate previous reports that shortened-or eliminated-HFI treatment with oral contraceptives is superior to placebo or a standard 21/7 regimen. Although the present study suffered from modest statistical power, there were no trends to suggest that better power would have resulted in significant effects.
The lack of significant differences between the two DROS conditions might be in part due to the relatively long half-life of DROS, which may have resulted in a somewhat shortened HFI even in the 21/7
condition. On the other hand, it is also quite possible that the effect of DROS-containing oral contraceptives on premenstrual symptoms is not robust; the beneficial effects of shortened-HFI oral contraceptives relative to placebo on premenstrual symptoms are inconsistent across studies , relatively small in size when they are found (Halbreich, 2014) , and often do not persist over follow-up . Further, a recent study observed that the beneficial premenstrual effects of COCs in some women may be undermined by a shifting of premenstrual symptoms into other chronological "phases" of the cycle (Lundin et al., 2017) ; on the other hand, various post hoc alternative specification of windows in the present study did not reveal consistent patterns of similar symptom shifting. In addition, although the robust placebo effect may have interfered with the detection of a potentially real therapeutic benefit of COC, this does not necessarily explain the failure to find a difference between the two active treatments (continuous vs. intermittent dosing). Our hypothesis that greater stabilization of ovarian steroids in the continuous (vs. intermittent) condition would lead to greater reduction of symptoms was not supported.
The present study adds to a body of RCTs in which oral contraceptive treatment effects in PMD are nonsignificant, small, or short-lived.
Given that COCs are among the most commonly prescribed treatments for PMD, this lack of consistent evidence warrants further investigation. Additional work is needed to understand and directly target the pathophysiology of PMD, and to understand the manner in which psychosocial contexts (e.g., treatment with placebo) influence PMD symptoms.
